Financial Performance - The company's operating revenue for 2023 is expected to be ¥190,895,915.28, a year-on-year increase of 0.35%[5] - The net profit attributable to shareholders is projected to be ¥58,720,669.50, reflecting a significant growth of 46.51% compared to the previous year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be ¥42,610,507.14, an increase of 12.28% year-on-year[6] - Basic earnings per share are anticipated to rise by 18.18% to ¥0.65[5] Assets and Equity - Total assets at the end of the reporting period are estimated to be ¥609,715,582.16, a decrease of 4.22% from the beginning of the period[5] - Shareholders' equity attributable to the company is expected to be ¥538,032,052.46, down 3.00% from the start of the period[5] Dividends and Share Repurchase - Cash dividends paid amounted to ¥54,909,600, and share repurchase payments totaled ¥27,736,000, contributing to the decline in total assets and equity[6] Government Incentives - The company received a government listing reward of ¥12 million during the reporting period[6] Sales and Gross Margin - The increase in sales revenue is attributed to a higher proportion of biological sample processing instruments, leading to a slight increase in overall gross margin[6] Cautionary Note - The financial data presented is preliminary and has not been audited, emphasizing the need for cautious investment decisions[7]
新芝生物(430685) - 2023 Q4 - 年度业绩